IPHA

Innate Pharma
IPHA

12 hedge funds and large institutions have $1.89M invested in Innate Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
12
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$32K
2
+$20.6K
3
+$6.74K
4
UBS Group
UBS Group
Switzerland
+$3.1K

Top Sellers

1
-$29.3K
2
-$20.9K
3
-$13.1K
4
TRCT
Tower Research Capital (TRC)
New York
-$7K
5
CS
Credit Suisse
Switzerland
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$965K
2
$371K
3
$330K
4
$114K
5
$38K
6
$32K
7
$29K
8
$9K
9
$1K
10
–
11
–
12
–